What is Cel-Sci Corporation's earnings per share (EPS)?

Cel-Sci Corporation (CVM) reported diluted earnings per share of -$6.27 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cel-Sci Corporation (CVM) Financials

CVM

FY2025 annual

Net Income -$25.4M +5.6% YoY

EPS (Diluted) -$6.27 YoY not available

Free Cash Flow -$17.2M +9.2% YoY

Operating Cash Flow -$17.1M +9.0% YoY

Market Cap $48.2M as of Oct 6, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 4.4x on $11.0M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE September

Newest figures come from the 10-Q for Q3 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CVM SEC filings page.

This page shows Cel-Sci Corporation (CVM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CVM FY2025 2026-10-03

CEL-SCI’s reported statements show a development-funded operation: recurring losses persist, while financing—not reported sales—has supplied the cash.

The latest net loss was $25.4M while operating cash flow was -$17.1M, so accounting improvement still had not become cash generation. Free cash flow was -$17.2M against operating cash flow of -$17.1M, indicating little capital reinvestment rather than an operating cash surplus.

R&D declined from $23.1M to $15.9M, pointing to a smaller development spending base. SG&A likewise fell from $13.1M to $8.9M, so the narrower loss appears expense-led rather than evidence of reported sales scale.

Financing cash flow was $23.4M against operating cash flow of -$17.1M, showing financing activity outweighed operating use. The current ratio recovered from 1.2x to 2.3x, indicating improved short-term coverage but not operating self-funding.

Financial Health Signals

Financial health score not available

Cel-Sci Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

4/6

Cel-Sci Corporation passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

Cel-Sci Corporation reported a net loss of $25.4M while operations used $17.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Cel-Sci Corporation reported an operating loss of $24.8M against $649K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$4.6M

YoY-1.8%

QoQ-5.5%

Cel-Sci Corporation's EBITDA was -$4.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.8% from the same quarter a year earlier. Against the prior quarter it is down 5.5%.

Net Income

-$5.7M

YoY0.0%

QoQ-3.7%

Cel-Sci Corporation reported -$5.7M in net income in Q3 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 3.7%.

EPS (Diluted)

-$0.47

Cel-Sci Corporation earned -$0.47 per diluted share (EPS) in Q3 2026.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow

-$4.0M

YoY-2.3%

QoQ-0.2%

Cel-Sci Corporation recorded an outflow of $4.0M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents a decrease of 2.3% from the same quarter a year earlier. Against the prior quarter it is down 0.2%.

Cash & Debt

$6.5M

YoY+264.1%

QoQ+245.2%

5Y CAGR-28.9%

10Y CAGR+2.3%

Cel-Sci Corporation held $6.5M in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

18M

5Y CAGR-16.4%

10Y CAGR-19.0%

Cel-Sci Corporation had 18M shares outstanding in Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity

-51.7%

YoY+28.9pp

QoQ+27.8pp

Cel-Sci Corporation's ROE was -51.7% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is up 28.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 27.8 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$3.6M

YoY-2.4%

QoQ-3.1%

Cel-Sci Corporation invested $3.6M in research and development in Q3 2026. This represents a decrease of 2.4% from the same quarter a year earlier. Against the prior quarter it is down 3.1%.

Capital Expenditures

Cel-Sci Corporation reported no capital expenditure in Q3 2026.

Share Buybacks

Not reported for Q3 2026.

CVM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CVM quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$264K+65.5%	$160K-37.3%	$255K-73.4%	$956K
R&D Expenses	N/A	$15.9M-12.5%	$18.2M-19.2%	$22.5M-11.4%	$25.4M+9.7%	$23.1M+29.5%	$17.8M+40.9%	$12.7M+16.0%	$10.9M-30.1%	$15.6M-10.5%	$17.4M-9.1%	$19.2M+25.7%	$15.3M+20.4%	$12.7M+22.3%	$10.4M-11.7%	$11.7M
SG&A Expenses	N/A	$8.9M+8.9%	$8.2M-9.0%	$9.0M-15.9%	$10.7M-18.2%	$13.1M+11.8%	$11.7M+46.3%	$8.0M+26.3%	$6.3M+9.2%	$5.8M-10.6%	$6.5M-53.2%	$13.9M+29.9%	$10.7M+52.7%	$7.0M+5.9%	$6.6M-1.0%	$6.7M
Operating Income	N/A	-$24.8M+5.9%	-$26.4M+16.3%	-$31.5M+12.7%	-$36.1M+0.4%	-$36.2M-24.9%	-$29.0M-43.5%	-$20.2M-20.4%	-$16.8M+21.7%	-$21.4M+9.5%	-$23.6M+27.0%	-$32.4M-26.2%	-$25.7M-29.2%	-$19.9M-15.2%	-$17.2M+4.1%	-$18.0M
EBITDA	N/A	-$22.8M+6.0%	-$24.2M+17.5%	-$29.4M+13.9%	-$34.1M+4.6%	-$35.7M-25.0%	-$28.6M-45.8%	-$19.6M-21.1%	-$16.2M+22.2%	-$20.8M+9.6%	-$23.0M+27.4%	-$31.7M-27.0%	-$25.0M-27.4%	-$19.6M-16.7%	-$16.8M+3.8%	-$17.5M
Interest Expense	N/A	$649K-13.0%	$746K+10.5%	$675K-37.5%	$1.1M+194.1%	-$1.1M-195.8%	$1.2M+166.8%	-$1.8M	N/A	N/A	-$1.9M-1545.9%	$130K-20.6%	$164K-3.9%	$170K-35.0%	$262K-18.8%	$323K
Net Income	N/A	-$25.4M+5.6%	-$26.9M+16.8%	-$32.4M+11.8%	-$36.7M-0.9%	-$36.4M-20.2%	-$30.3M-36.7%	-$22.1M+30.5%	-$31.8M-121.7%	-$14.4M-24.8%	-$11.5M+66.8%	-$34.7M-26.8%	-$27.4M-198.3%	-$9.2M+40.7%	-$15.5M+39.8%	-$25.7M
EPS (Basic)	N/A	N/A	N/A	N/A	-$0.87+3.3%	-$0.90-9.8%	-$0.82-15.5%	-$0.71+62.0%	-$1.87-2.2%	-$1.83+22.8%	-$2.37+77.5%	-$10.51+13.1%	-$12.10-3933.3%	-$0.30+57.1%	-$0.70+45.3%	-$1.28
EPS (Diluted)	—	-$6.27	-$15.31	-$0.73+16.1%	-$0.87+3.3%	-$0.90-9.8%	-$0.82-15.5%	-$0.71	-$1.87	-$1.91	-$2.37	-$10.51+13.9%	-$12.21	-$0.66	-$0.78+47.7%	-$1.49
Diluted Shares (Avg)	N/A	4M	2M	44M+3.1%	43M+6.0%	41M+10.7%	37M+17.9%	31M	17M	8M	5M	3M	N/A	N/A	252M+20.8%	208M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
R&D Expenses	$3.6M-2.4%	$3.8M-6.2%	$3.7M-17.0%	N/A	$3.7M-20.5%	$4.0M-13.3%	$4.4M+1.8%	N/A
SG&A Expenses	$1.9M+9.1%	$1.6M-34.5%	$1.7M-31.3%	N/A	$1.7M-11.1%	$2.4M-2.8%	$2.5M+15.5%	N/A
Operating Income	-$5.6M-1.2%	-$5.3M+16.7%	-$5.4M+22.1%	N/A	-$5.5M+17.7%	-$6.4M+9.6%	-$6.9M-6.3%	N/A
EBITDA	-$4.6M-1.8%	-$4.4M+19.4%	-$4.4M+25.3%	N/A	-$4.5M+20.3%	-$5.4M+10.9%	-$5.9M-7.6%	N/A
Interest Expense	$111K-35.5%	$117K-34.3%	$88K-48.2%	N/A	$172K+190.2%	$178K+197.4%	$170K+186.0%	N/A
Net Income	-$5.7M0.0%	-$5.5M+16.8%	-$5.5M+22.7%	N/A	-$5.7M+17.4%	-$6.6M+9.3%	-$7.1M-5.4%	N/A
EPS (Diluted)	-$0.47	-$0.67	-$0.68	$0.07	-$1.36	-$2.33	-$3.25	-$2.80
Diluted Shares (Avg)	12M	8M	8M	N/A	4M	3M	2M	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax, EPS (Basic).

CVM Balance Sheet

CVM quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$28.2M+4.3%	$27.0M-11.6%	$30.5M-39.6%	$50.5M-33.4%	$75.9M+87.2%	$40.5M+46.7%	$27.6M-6.6%	$29.6M+29.1%	$22.9M-7.9%	$24.9M-12.8%	$28.6M+48.5%	$19.2M+77.4%	$10.8M-32.5%	$16.1M-13.7%	$18.6M
Current Assets	$11.6M+91.5%	$6.1M-12.5%	$6.9M-72.8%	$25.4M-43.8%	$45.3M+155.8%	$17.7M+80.3%	$9.8M-14.2%	$11.4M+170.0%	$4.2M-22.4%	$5.5M-34.6%	$8.3M-28.4%	$11.6M+363.8%	$2.5M-66.2%	$7.4M-17.5%	$9.0M
Cash & Equivalents	$11.0M+131.2%	$4.7M+14.3%	$4.1M-81.7%	$22.7M-37.1%	$36.1M+132.5%	$15.5M+83.7%	$8.4M-18.1%	$10.3M+335.1%	$2.4M-18.8%	$2.9M-49.0%	$5.7M-32.7%	$8.5M+20359.5%	$42K-98.9%	$3.9M-7.5%	$4.3M
Short-Term Investments	$0	$0	$0	$0-100.0%	$6.2M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	$1.0M-54.6%	$2.2M+12.3%	$2.0M-0.2%	$2.0M+144.7%	$820K+4.8%	$782K+21.3%	$645K-4.1%	$673K-33.3%	$1.0M-28.0%	$1.4M-3.5%	$1.5M+42.8%	$1.0M-26.6%	$1.4M-11.9%	$1.6M
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$55K0.0%	$55K-12.5%	$63K-47.1%	$119K-45.7%	$218K-44.6%	$395K+352.4%	$87K+6.6%	$82K+10.2%	$74K-53.2%	$159K-65.3%	$457K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$12.2M-13.6%	$14.1M-18.4%	$17.3M-5.7%	$18.4M-5.0%	$19.3M-7.1%	$20.8M-7.5%	$22.5M-24.0%	$29.6M+12.7%	$26.3M+2.7%	$25.6M-23.3%	$33.3M+279.1%	$8.8M+112.3%	$4.1M-54.2%	$9.0M-5.3%	$9.5M
Current Liabilities	$5.1M+11.2%	$4.6M-17.4%	$5.6M+19.8%	$4.7M+18.5%	$3.9M-7.7%	$4.3M+41.3%	$3.0M-67.3%	$9.2M-14.9%	$10.8M+170.3%	$4.0M-40.2%	$6.7M+112.7%	$3.2M-11.1%	$3.5M+85.4%	$1.9M-73.5%	$7.2M
Non-Current Liabilities	$7.1M-25.7%	$9.5M-18.9%	$11.7M-14.4%	$13.7M-11.1%	$15.4M-6.9%	$16.5M-15.0%	$19.5M-4.4%	$20.4M+32.1%	$15.4M-28.5%	$21.6M-19.0%	$26.6M+372.3%	$5.6M+849.5%	$593K-91.7%	$7.1M+206.9%	$2.3M
Long-Term Debt	$5.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.0M+24.0%	$12.9M-2.6%	$13.2M-58.9%	$32.2M-43.1%	$56.5M+186.6%	$19.7M+284.3%	$5.1M+560344.0%	$916+100.0%	-$3.3M-391.3%	-$679K+85.7%	-$4.8M-144.2%	$10.8M+61.0%	$6.7M-4.7%	$7.0M-22.6%	$9.1M
Retained Earnings	-$539.4M-4.9%	-$514.0M-5.5%	-$487.1M-7.1%	-$454.9M-8.8%	-$418.2M-9.5%	-$381.8M-7.9%	-$353.7M-6.7%	-$331.6M-10.6%	-$299.8M-5.0%	-$285.4M-4.2%	-$273.9M-14.5%	-$239.2M-12.9%	-$211.8M-4.4%	-$203.0M-8.3%	-$187.5M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$21.4M+5.0%	$17.7M-18.8%	$22.9M-10.9%	$28.2M+4.3%	$20.3M-15.5%	$21.8M-27.4%	$25.7M-10.5%	$27.0M-11.6%
Current Assets	$7.5M+186.1%	$2.9M-4.3%	$7.0M+20.0%	$11.6M+91.5%	$2.6M-26.0%	$3.0M-64.5%	$5.9M-4.8%	$6.1M-12.5%
Cash & Equivalents	$6.5M+264.1%	$1.9M-1.7%	$6.3M+36.1%	$11.0M+131.2%	$1.8M+366.1%	$1.9M-63.8%	$4.6M+42.3%	$4.7M+14.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.0M-54.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$10.4M-21.9%	$10.8M-21.6%	$11.8M-18.3%	$12.2M-13.6%	$13.3M-14.6%	$13.8M-12.3%	$14.4M-10.4%	$14.1M-18.4%
Current Liabilities	$5.1M-9.6%	$4.8M-12.6%	$5.0M-8.0%	$5.1M+11.2%	$5.6M+2.0%	$5.5M+8.1%	$5.5M+12.6%	$4.6M-17.4%
Non-Current Liabilities	$5.3M-30.9%	$6.0M-27.5%	$6.7M-24.6%	$7.1M-25.7%	$7.7M-23.7%	$8.3M-22.0%	$8.9M-20.4%	$9.5M-18.9%
Long-Term Debt	N/A	N/A	N/A	$5.7M	N/A	N/A	N/A	N/A
Total Equity	$11.0M+56.0%	$6.9M-14.0%	$11.1M-1.5%	$16.0M+24.0%	$7.0M-17.1%	$8.0M-44.1%	$11.3M-10.6%	$12.9M-2.6%
Retained Earnings	-$556.0M-4.3%	-$550.4M-4.3%	-$544.9M-4.6%	-$539.4M-4.9%	-$533.3M-5.0%	-$527.7M-5.3%	-$521.1M-5.5%	-$514.0M-5.5%

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.

CVM Cash Flow Statement

CVM quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$16.7M	-$17.1M+9.0%	-$18.8M+17.7%	-$22.8M-25.3%	-$18.2M+2.9%	-$18.8M-23.0%	-$15.3M+6.4%	-$16.3M-21.9%	-$13.4M+2.9%	-$13.8M+40.2%	-$23.1M+3.2%	-$23.8M-3.9%	-$22.9M-69.2%	-$13.5M-11.1%	-$12.2M+46.0%	-$22.6M
Depreciation & Amortization	N/A	$2.1M-3.7%	$2.1M+1.0%	$2.1M+6.9%	$2.0M+342.3%	$447K+14.9%	$389K-33.8%	$588K+2.3%	$575K-3.0%	$593K-5.3%	$626K-7.9%	$680K-3.3%	$703K+154.8%	$276K-38.3%	$447K-15.8%	$531K
Stock-Based Compensation	N/A	$1.9M-55.2%	$4.3M-32.1%	$6.3M-44.8%	$11.4M-16.8%	$13.7M+35.3%	$10.1M+128.4%	$4.4M+61.4%	$2.7M+98.7%	$1.4M-34.7%	$2.1M-58.6%	$5.1M+29.0%	$4.0M+50.1%	$2.6M+18.3%	$2.2M+45.2%	$1.5M
Capital Expenditures	$5K	$38K-59.8%	$95K-73.8%	$362K-43.3%	$638K-92.9%	$9.0M+239.6%	$2.7M+1393.4%	-$178K+17415.2%	$1K-90.4%	$11K-66.5%	$31K-57.2%	$73K-29.4%	$104K+1.9%	$102K+86.7%	$55K-74.8%	$217K
Free Cash Flow	-$16.8M	-$17.2M+9.2%	-$18.9M+18.5%	-$23.2M-22.9%	-$18.9M+32.1%	-$27.8M-55.1%	-$17.9M-8.7%	-$16.5M-23.2%	-$13.4M+3.0%	-$13.8M+40.3%	-$23.1M+3.3%	-$23.9M-3.8%	-$23.0M-68.7%	-$13.7M-11.5%	-$12.2M+46.2%	-$22.8M
Investing Cash Flow	-$5K	-$38K+64.7%	-$108K+71.0%	-$372K-106.8%	$5.5M+136.2%	-$15.2M-463.5%	-$2.7M-702.4%	-$336K-477.6%	-$58K-242.0%	-$17K+50.3%	-$34K+63.4%	-$94K+32.6%	-$139K-4.6%	-$133K+0.6%	-$134K+58.0%	-$318K
Financing Cash Flow	$21.5M	$23.4M+19.8%	$19.5M+315.6%	$4.7M+835.3%	-$638K-101.2%	$54.5M+117.8%	$25.0M+69.3%	$14.8M-30.8%	$21.4M+61.3%	$13.3M-34.7%	$20.3M-3.9%	$21.1M-33.0%	$31.5M+222.4%	$9.8M-18.5%	$12.0M+2021.3%	$566K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$4.0M-2.3%	-$4.0M+7.9%	-$4.0M+2.8%	-$4.7M+3.0%	-$3.9M+14.0%	-$4.4M+3.5%	-$4.1M+15.3%	-$4.8M+4.5%
Depreciation & Amortization	$946K-1.3%	$956K-1.4%	$964K-3.1%	N/A	$959K-2.6%	$970K-1.9%	$995K-0.9%	N/A
Stock-Based Compensation	N/A	N/A	$443K-37.7%	N/A	N/A	N/A	$711K-48.6%	N/A
Capital Expenditures	$0	$0	$0-100.0%	$5K-73.9%	$0-100.0%	$0	$33K-36.2%	$20K
Free Cash Flow	-$4.0M-2.3%	-$4.0M+7.9%	-$4.0M+3.6%	-$4.7M+3.3%	-$3.9M+14.4%	-$4.4M+3.5%	-$4.2M+15.5%	-$4.8M+4.1%
Investing Cash Flow	$0	$0	$0+100.0%	-$5K+73.9%	$0+100.0%	$0	-$33K+49.2%	-$20K-90.5%
Financing Cash Flow	$8.7M+127.6%	-$364K-121.7%	-$654K-116.1%	$13.8M+50.6%	$3.8M+1281.6%	$1.7M-74.5%	$4.0M0.0%	$9.2M+126.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CVM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CVM quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-9721.4%	-12450.1%	-6772.3%	-1881.0%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-10359.6%	-5746.8%	-6078.8%	-2689.1%
Return on Equity	-159.3%+50.0pp	-209.2%+35.7pp	-244.9%-130.8pp	-114.1%-49.8pp	-64.3%+89.1pp	-153.4%+277.8pp	-431.2%+3475246.2pp	-3475677.4%	N/A	N/A	N/A	-253.7%-116.8pp	-136.9%+83.4pp	-220.2%+63.0pp	-283.2%
Return on Assets	-90.3%+9.5pp	-99.7%+6.3pp	-106.0%-33.4pp	-72.6%-24.7pp	-47.9%+26.7pp	-74.6%+5.5pp	-80.1%+27.5pp	-107.6%-45.0pp	-62.7%-16.4pp	-46.3%+75.2pp	-121.5%+20.7pp	-142.2%-57.6pp	-84.6%+11.7pp	-96.3%+41.7pp	-138.1%
Current Ratio	2.26+0.9x	1.31+0.1x	1.24-4.2x	5.45-6.0x	11.50+7.3x	4.15+0.9x	3.25+2.0x	1.24+0.8x	0.39-1.0x	1.36+0.1x	1.24-2.5x	3.69+3.0x	0.71-3.2x	3.89+2.6x	1.25
Debt-to-Equity	0.36-0.7x	1.10-0.2x	1.31+0.7x	0.57+0.2x	0.34-0.7x	1.05-3.3x	4.38-32294.2x	32298.59	N/A	N/A	N/A	0.81+0.2x	0.62-0.7x	1.29+0.2x	1.05
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.010.0x	0.010.0x	0.020.0x	0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-8723.1%	-8553.9%	-4809.2%	-2381.6%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Return on Equity	-51.7%+28.9pp	-79.5%+2.7pp	-49.1%+13.4pp	N/A	-80.6%+0.3pp	-82.2%-31.5pp	-62.5%-9.5pp	N/A
Return on Assets	-26.5%+1.3pp	-30.9%-0.7pp	-23.9%+3.6pp	N/A	-27.9%+0.6pp	-30.1%-6.0pp	-27.5%-4.2pp	N/A
Current Ratio	1.48+1.0x	0.60+0.1x	1.39+0.3x	2.26+0.9x	0.47-0.2x	0.55-1.1x	1.07-0.2x	1.31+0.1x
Debt-to-Equity	0.95-0.9x	1.58-0.2x	1.06-0.2x	0.36-0.7x	1.89+0.1x	1.73+0.6x	1.270.0x	1.10-0.2x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Cel-Sci Corporation CVM	FY2025	N/A	-$25.4M	N/A	$48.2M	—
ANEBULO PHARMAC INC ANEB	FY2025	N/A	-$8.5M	N/A	$14.7M	—
Adicet Bio, Inc. ACET	FY2025	N/A	-$116.8M	N/A	$60.6M	—
Atara Biotherapeutics, Inc ATRA	FY2025	$120.8M	$32.7M	27.1%	$94.4M	63/100
Immunic, Inc. IMUX	FY2025	N/A	-$97.2M	N/A	$110.1M	—

Where Cel-Sci Corporation Ranks

Frequently Asked Questions

Is Cel-Sci Corporation profitable?

No, Cel-Sci Corporation (CVM) reported a net income of -$25.4M in fiscal year 2025.

What is Cel-Sci Corporation's EBITDA?

Cel-Sci Corporation (CVM) had EBITDA of -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cel-Sci Corporation have?

As of fiscal year 2025, Cel-Sci Corporation (CVM) had $11.0M in cash and equivalents against $5.7M in long-term debt.

What is Cel-Sci Corporation's return on equity (ROE)?

Cel-Sci Corporation (CVM) has a return on equity of -159.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cel-Sci Corporation's free cash flow?

Cel-Sci Corporation (CVM) recorded an outflow of $17.2M in free cash flow during fiscal year 2025. This represents a 9.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cel-Sci Corporation's operating cash flow?

Cel-Sci Corporation (CVM) recorded an outflow of $17.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Cel-Sci Corporation's total assets?

Cel-Sci Corporation (CVM) had $28.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cel-Sci Corporation's capital expenditures?

Cel-Sci Corporation (CVM) invested $38K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cel-Sci Corporation spend on research and development?

Cel-Sci Corporation (CVM) invested $15.9M in research and development during fiscal year 2025.

How many shares does Cel-Sci Corporation have outstanding?

Cel-Sci Corporation (CVM) had 8M shares outstanding as of fiscal year 2025.

What is Cel-Sci Corporation's current ratio?

Cel-Sci Corporation (CVM) had a current ratio of 2.26 as of fiscal year 2025, which is generally considered healthy.

What is Cel-Sci Corporation's debt-to-equity ratio?

Cel-Sci Corporation (CVM) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cel-Sci Corporation's return on assets (ROA)?

Cel-Sci Corporation (CVM) had a return on assets of -90.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cel-Sci Corporation's P/E ratio?

Cel-Sci Corporation (CVM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $48.2M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Cel-Sci Corporation's price-to-sales ratio?

Cel-Sci Corporation (CVM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $48.2M as of Oct 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Cel-Sci Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Cel-Sci Corporation (CVM) held $11.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.1M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Cel-Sci Corporation's Piotroski F-Score?

Cel-Sci Corporation (CVM) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cel-Sci Corporation's earnings high quality?

Cel-Sci Corporation (CVM) reported a net loss of $25.4M while operations used $17.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cel-Sci Corporation cover its interest payments?

Cel-Sci Corporation (CVM) reported an operating loss of $24.8M against $649K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.